{"type":"PR","pr":{"number":167,"head":"cc11a57561952de78af35e298a88455f0d090d9e"},"user":"silvia.vernotico","status":"draft","branch":"cms/2019-02-09-hot-this-week-in-farmaceutica-younger-n-87","collection":"hotthisweek","title":"HOT THIS WEEK IN FARMACEUTICA YOUNGER N.87","description":"La Food and Drug Administration degli Stati Uniti ha approvato Cablivi (caplacizumab-yhdp), la prima terapia specificatamente indicata, in combinazione con lo scambio plasmatico e la terapia immunosoppressiva, per il trattamento di pazienti adulti con porpora trombotica trombocitopenica acquisita (aTTP â€“ acquired thrombocitic thrombocytopenic purpura).","objects":{"entry":{"path":"site/content/hotthisweek/2019-02-09-hot-this-week-in-farmaceutica-younger-n-87.md","sha":"86926e864d52218e6e7ec1e333293912d51564cd"},"files":[]},"timeStamp":"2019-02-10T07:56:47.925Z"}